PledPharma AB today announced that the Annual Report for 2019 now is available at the company’s website, www.pledpharma.se.
A printed version can be ordered through [email protected] or +468 -679 72 10.
March 30, 2020
PledPharma AB today announced that the Annual Report for 2019 now is available at the company’s website, www.pledpharma.se.
A printed version can be ordered through [email protected] or +468 -679 72 10.
Contacts
Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]
Yilmaz Mahshid, CFO, phone: +46 72 231 68 00
[email protected]
About Us
PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/